Bavituximab Appeared Generally Safe and Well Tolerated at All Doses Tested
TUSTIN, CA, USA and BOSTON, MA, USA | November 5, 2007 | Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that results from its Phase lb study of bavituximab in chronic HCV patients were discussed on Sunday in an oral presentation at the 58th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) — The Liver Meeting(R). The study results were presented by Dr. Eric J. Lawitz, a principal investigator of the Phase lb study and director of Alamo Medical Research.
The multiple dose, open label study was designed to assess the safety and pharmacokinetic properties of ascending dose levels of bavituximab administered as monotherapy in patients with chronic HCV infection. Other study objectives included evaluation of anti-viral activity as measured by changes in serum HCV virus levels and an exploratory analysis of changes in serum cytokine levels as a measure of bavituximab’s ability to stimulate certain components of the immune system.
Results indicate that bavituximab was generally safe and well tolerated, with no dose limiting toxicities or serious adverse events reported. Anti-viral activity (decline of greater than or equal to 0.5 log10 reduction in HCV RNA) was observed at all dose levels and was most consistent in patients receiving 3 mg/kg of bavituximab. In this cohort, 83% of the patients demonstrated anti-viral activity. An assessment of the cytokine profile in this cohort also suggests bavituximab induces a pro-inflammatory cytokine profile, defined as an increase in the ratio of TNF alpha and TGF beta. Stimulating an immune response is a key proposed anti-viral mechanism of action of bavituximab.
"Meeting all of the objectives of this Phase l trial was an important milestone for the bavituximab HCV program," said Steven W. King, president and CEO of Peregrine. "We are particularly pleased with bavituximab’s positive safety profile at all doses tested, its predictable and consistent pharmacokinetic characteristics, and the signs of anti-viral activity and immune system stimulation that were observed. Based on these results, we have been able to identify a target dose range of 3 mg/kg for future clinical studies."
Twenty-four patients received bavituximab twice weekly for two weeks at escalating dose levels of 0.3, 1, 3, or 6 mg/kg of body weight. They were followed through week 12 of the study. All study patients had chronic HCV infection based on their medical history and the presence of detectable serum HCV RNA and elevated liver enzymes. More than half of the patients had genotype 1 HCV, the most difficult-to-treat strain. This study included treatment naive patients, patients who were partial responders to standard interferon/ribavirin HCV treatment regimens, and patients who were non-responders or treatment failures when given standard HCV regimens.
"Future hepatitis C therapy will likely require multiple mechanisms of action, including an immune modulating agent," said Dr. Lawitz. "Bavituximab has a novel targeted immunomodulatory mechanism and if proven effective, it has the potential to be complementary to emerging new anti-viral therapies for HCV infection."
Peregrine has initiated a new bavituximab trial in HCV patients co-infected with HIV and is planning additional combination therapy HCV studies.
About Bavituximab
Bavituximab is the first investigational agent in a new class of anti-phosphotidylserine (PS) monoclonal antibody immunotherapeutics that target and bind to cellular components that are normally not present on the outside of cells, but which become exposed on certain virally infected cells and on the surface of enveloped viruses. Bavituximab helps stimulate the body’s immune defenses to destroy both the virus particles and the infected cells. Since bavituximab’s PS target comes from the host and not the virus, bavituximab is expected to be less susceptible to the development of anti-viral resistance than many other therapies. Bavituximab has successfully completed two Phase l clinical trials as monotherapy in patients with chronic HCV infection and is currently being assessed in a trial for the treatment of HCV in patients co-infected with HIV. Similar to the proposed anti-viral mechanism, anti-PS antibodies also bind to phospholipids exposed on tumor blood vessels in all solid cancers tested to date. Bavituximab has successfully completed a Phase l trial in combination with chemotherapy in patients with advanced solid tumors. Protocols for three Phase ll cancer trials in combination with chemotherapy are undergoing regulatory review.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that bavituximab’s safety profile in a combination therapy trial will not be at the same safety level as was found in the Phase 1b trial, the risk that the results of future trials will not correlate to the results from the Phase 1b trial, the risk that the early signs of immune stimulation may not be confirmed and the uncertainties as to whether bavituximab will be effective against chronic HCV when used in combination with antiviral drugs. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended July 31, 2007. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE: Peregrine Pharmaceuticals
Post Views: 126
Bavituximab Appeared Generally Safe and Well Tolerated at All Doses Tested
TUSTIN, CA, USA and BOSTON, MA, USA | November 5, 2007 | Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that results from its Phase lb study of bavituximab in chronic HCV patients were discussed on Sunday in an oral presentation at the 58th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) — The Liver Meeting(R). The study results were presented by Dr. Eric J. Lawitz, a principal investigator of the Phase lb study and director of Alamo Medical Research.
The multiple dose, open label study was designed to assess the safety and pharmacokinetic properties of ascending dose levels of bavituximab administered as monotherapy in patients with chronic HCV infection. Other study objectives included evaluation of anti-viral activity as measured by changes in serum HCV virus levels and an exploratory analysis of changes in serum cytokine levels as a measure of bavituximab’s ability to stimulate certain components of the immune system.
Results indicate that bavituximab was generally safe and well tolerated, with no dose limiting toxicities or serious adverse events reported. Anti-viral activity (decline of greater than or equal to 0.5 log10 reduction in HCV RNA) was observed at all dose levels and was most consistent in patients receiving 3 mg/kg of bavituximab. In this cohort, 83% of the patients demonstrated anti-viral activity. An assessment of the cytokine profile in this cohort also suggests bavituximab induces a pro-inflammatory cytokine profile, defined as an increase in the ratio of TNF alpha and TGF beta. Stimulating an immune response is a key proposed anti-viral mechanism of action of bavituximab.
"Meeting all of the objectives of this Phase l trial was an important milestone for the bavituximab HCV program," said Steven W. King, president and CEO of Peregrine. "We are particularly pleased with bavituximab’s positive safety profile at all doses tested, its predictable and consistent pharmacokinetic characteristics, and the signs of anti-viral activity and immune system stimulation that were observed. Based on these results, we have been able to identify a target dose range of 3 mg/kg for future clinical studies."
Twenty-four patients received bavituximab twice weekly for two weeks at escalating dose levels of 0.3, 1, 3, or 6 mg/kg of body weight. They were followed through week 12 of the study. All study patients had chronic HCV infection based on their medical history and the presence of detectable serum HCV RNA and elevated liver enzymes. More than half of the patients had genotype 1 HCV, the most difficult-to-treat strain. This study included treatment naive patients, patients who were partial responders to standard interferon/ribavirin HCV treatment regimens, and patients who were non-responders or treatment failures when given standard HCV regimens.
"Future hepatitis C therapy will likely require multiple mechanisms of action, including an immune modulating agent," said Dr. Lawitz. "Bavituximab has a novel targeted immunomodulatory mechanism and if proven effective, it has the potential to be complementary to emerging new anti-viral therapies for HCV infection."
Peregrine has initiated a new bavituximab trial in HCV patients co-infected with HIV and is planning additional combination therapy HCV studies.
About Bavituximab
Bavituximab is the first investigational agent in a new class of anti-phosphotidylserine (PS) monoclonal antibody immunotherapeutics that target and bind to cellular components that are normally not present on the outside of cells, but which become exposed on certain virally infected cells and on the surface of enveloped viruses. Bavituximab helps stimulate the body’s immune defenses to destroy both the virus particles and the infected cells. Since bavituximab’s PS target comes from the host and not the virus, bavituximab is expected to be less susceptible to the development of anti-viral resistance than many other therapies. Bavituximab has successfully completed two Phase l clinical trials as monotherapy in patients with chronic HCV infection and is currently being assessed in a trial for the treatment of HCV in patients co-infected with HIV. Similar to the proposed anti-viral mechanism, anti-PS antibodies also bind to phospholipids exposed on tumor blood vessels in all solid cancers tested to date. Bavituximab has successfully completed a Phase l trial in combination with chemotherapy in patients with advanced solid tumors. Protocols for three Phase ll cancer trials in combination with chemotherapy are undergoing regulatory review.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that bavituximab’s safety profile in a combination therapy trial will not be at the same safety level as was found in the Phase 1b trial, the risk that the results of future trials will not correlate to the results from the Phase 1b trial, the risk that the early signs of immune stimulation may not be confirmed and the uncertainties as to whether bavituximab will be effective against chronic HCV when used in combination with antiviral drugs. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended July 31, 2007. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE: Peregrine Pharmaceuticals
Post Views: 126
